BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Takeda Pharmaceutical Co. Ltd. (TKDG.DE) in Talks to Buy Cipla Ltd., Lupin Ltd. (LUPN.BO) Drug Business; Companies Deny Rumor


8/24/2011 7:11:43 AM

In a bid to broaden its global reach, Takeda Pharmaceuticals is holding talks with two of India’s biggest drugmakers - Cipla and Lupin - both of which are large providers of generic meds, according to reports. The move underscores the ongoing desire among brand-name drugmakers to gain market share in the large Indian market as well as expand their product portfolios. Takeda, which earlier this year bought Nycomed for $13.6 billion, is talking to Lupin about buying its domestic formulations business and research facility, according to The Economic Times, although Lupin apparently wants a price that would amount to 17 times revenue, which last year reached $1.5 billion. The Japanese drugmaker has also approached Cipla, but talks were described as preliminary.

Read at Pharmalot
Read at Money Control
Read at Reuters
Read at EconomicTimes

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES